ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases.
We believe that a diverse product portfolio is key to our success and ability to bring the right therapy to the right patient at the right time. To that end, we have expanded our drug discovery efforts to encompass development in both targeted and immunotherapy areas.
Our lead compound, Abivertinib, a small molecule kinase inhibitor, is currently under review by the China Food and Drug Administration (CFDA) for the treatment of patients with non-small cell lung cancer (NSCLC) containing the EGFR T790M mutation. A second small molecule kinase inhibitor, AC0058, has entered Phase 1B development in the US for the treatment of systemic lupus erythematosus (SLE).
Alongside a robust R&D organization, ACEA has established drug manufacturing and commercial capabilities in China to support our long-term growth. This infrastructure provides us greater control over our supply chain to make sure products are delivered to patients on-time and at the highest quality.
We believe ACEA is well-position to deliver on its promise to bring innovative treatments to patients living with life-threatening diseases while creating value for shareholders, employees, and society.